Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases

NCT06733935 is registered in ClinicalTrials.gov with Nkarta, Inc. as lead sponsor.

NCT NCT06733935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06733935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases
Lead sponsor
Nkarta, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 4, 2024
Completion date
October 31, 2028
Enrollment
240 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

antineutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathies, rheumatoid arthritis, systemic sclerosis